OLD Second National Bank of Aurora Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

OLD Second National Bank of Aurora lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,195 shares of the medical research company’s stock after selling 97 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Thermo Fisher Scientific were worth $634,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Bornite Capital Management LP grew its stake in shares of Thermo Fisher Scientific by 50.0% in the 1st quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after purchasing an additional 10,000 shares during the last quarter. Fairfield Bush & CO. lifted its holdings in shares of Thermo Fisher Scientific by 1.2% in the 1st quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after buying an additional 36 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of Thermo Fisher Scientific by 563.5% in the 1st quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after buying an additional 16,853 shares during the period. Covestor Ltd lifted its holdings in shares of Thermo Fisher Scientific by 60.5% in the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after buying an additional 121 shares during the period. Finally, Merit Financial Group LLC raised its holdings in Thermo Fisher Scientific by 3.6% during the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after purchasing an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,277 shares of company stock valued at $28,513,384. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TMO. Raymond James lifted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Citigroup began coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. The Goldman Sachs Group boosted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $4.13 during trading hours on Thursday, reaching $543.12. 869,099 shares of the stock were exchanged, compared to its average volume of 1,530,491. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The firm has a 50 day simple moving average of $571.57 and a 200-day simple moving average of $527.01. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The stock has a market capitalization of $207.31 billion, a P/E ratio of 35.42, a P/E/G ratio of 2.33 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The business’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the business posted $5.40 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.